Abstract
Background: Tyroserleutide (YSL) inhibits the growth and metastasis of human hepatocellular carcinoma (HCC). This paper studied the effect of YSL on metastasis of human HCC and investigated its mechanisms. Methods: In vivo, experimental lung metastasis models of human HCC SK-HEP-1 cells in nude mice were established, and In vitro, the proliferation, adhesion and invasion of SK-HEP-1 cells were detected. Results: In vivo, YSL significantly inhibited the metastasis of human HCC. In vitro, YSL significantly inhibited the proliferation, adhesion and invasion of SK-HEP-1 cells. Through analyses with reverse transcription PCR (RT-PCR) and Western blot, we observed that YSL significantly inhibited the expressions of ICAM-1 in SK-HEP-1 cells. Through RT-PCR, Western blot and zymography methods, YSL was discovered to decrease the mRNA level, protein expression and activity of MMP-2 and -9 in SK-HEP-1 cells. Conclusion: We concluded that YSL could inhibit tumor growth and metastasis of human HCC SK-HEP-1 cells.
Cite
CITATION STYLE
Che, X., Lu, R., Fu, Z., Sun, Y., Zhu, Z. F., Lli, J. P., … Yao, Z. (2018). Therapeutic effects of tyroserleutide on lung metastasis of human hepatocellular carcinoma SsK-HEheP-1 and its mechanism affecting ICAicaM-1 and MMP-2 and -9. Drug Design, Development and Therapy, 12, 3357–3368. https://doi.org/10.2147/DDDT.S177126
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.